H
Hangzhou Ruipu Chenchuang Technology
A regenerative medicine company leveraging stem cell therapy to address diabetes, with plans to expand its application to other disease areas
About Hangzhou Ruipu Chenchuang Technology
Hangzhou Ruipu Chenchuang Technology, operating as ReproGenix Bioscience, is a regenerative medicine company established in 2014, with a strategic focus on developing stem cell-based therapies. The company was co-founded by Professor Hongkui Deng, a distinguished stem cell researcher and Director of the Peking University Stem Cell Research Center; Dr. Lieming Ding, a seasoned pharmaceutical industry leader; and Casey Lou, a serial entrepreneur who serves as CEO. Professor Deng's pioneering work in non-genetic cellular reprogramming technologies provides the scientific foundation for the company's core technology.
ReproGenix is centered on the clinical application of chemically induced pluripotent stem cells (CiPSCs) to address significant unmet medical needs, primarily diabetes. The company's business model involves intensive research and development to bring proprietary cell therapies through clinical trials to commercialization. Its operations encompass a comprehensive platform that integrates research, manufacturing under GMP conditions, and clinical translation. The company's lead product is RGB-5088, an islet cell injection derived from CiPSCs designed for diabetes therapy. This product represents a potential paradigm shift, moving from disease management to a curative-intent therapy.
A landmark achievement for the company was the successful treatment of a type 1 diabetes patient, who became insulin-independent within 75 days of receiving the RGB-5088 transplant, a result that was replicated in subsequent patients. This breakthrough, published in the journal *Cell*, demonstrated the safety and efficacy of the therapy in a pilot clinical study. Following these results, RGB-5088 received Investigational New Drug (IND) approval in China, and a Phase 1 clinical trial has commenced. ReproGenix anticipates starting Phase 2/3 trials in 2026, with a target for a Biologics License Application (BLA) filing in China by 2027. To support its clinical pipeline and bioprocess optimization, the company plans to raise significant capital.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 20.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Oncology, Spinout, Biotech and Pharma, Cell Therapy, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Nov 2025 | $69M | $344M | Betta Pharmaceuticals · Yuansheng BioVenture · Chinese Reform Holdings Corporation · Gage Finance | ↗ |
| SERIES AOther financing | Nov 2024 | $14M | $55M | Lenovo Capital and Incubator Group (LCIG) · Hetang Venture Capital Management (Beijing) · China Ventures Fund · Beda Pharmaceuticals | ↗ |
Growth signals
Latest recorded traffic for Hangzhou Ruipu Chenchuang Technology is 180 monthly website visits, up 0% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hangzhou Ruipu Chenchuang Technology in the Hangzhou ecosystem
The Hangzhou Ruipu Chenchuang Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
- CFChina Ventures Fund
Lenovo Capital and Incubator Group (LCIG)- H(Hetang Venture Capital Management (Beijing)
Beda Pharmaceuticals- BPBetta Pharmaceuticals
Yuansheng BioVenture- CCChinese Reform Holdings Corporation
- GFGage Finance
- SISinowisdom
- YGYuhang Guotou
- HMHangzhou Oriental Jiafu Asset Management
ZSCO
Other known investors1 additional known investor
Peking University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hangzhou Ruipu Chenchuang Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hangzhou Ruipu Chenchuang Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









